Key result
Therapeutic angiogenesis shows potential for advanced CAD, but no single modality emerges as superior.
A significant percentage of patients have coronary artery disease that is too advanced or diffuse for percutaneous or surgical intervention. Therapeutic angiogenesis is a treatment modality to induce vessel formation that is being developed for patients with advanced coronary disease not amenable to currently available interventions. A number of approaches to induce coronary collateralization are being developed. These include gene, protein, cellular and miRNA modalities, each of which have advantages and disadvantages. At this time, no modality has emerged as the single clear choice, and combination therapies may provide synergistic benefits. However, there have been a number of recent studies advancing our knowledge as to how we can refine procollateralizing treatments. In this article, we will examine some recent successes and future obstacles in the effort to bring therapeutic angiogenesis to patients.
No takes yet. Share an insight, caveat, or question.
Robich et al. (2011) conducted a review in Advanced coronary artery disease. Therapeutic angiogenesis was evaluated. Therapeutic angiogenesis modalities are being developed for advanced coronary artery disease, though no single approach has yet emerged as the clear choice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: